Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Epigenomics AG    ECX   DE000A11QW50

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

DGAP-DD: Epigenomics AG english

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2017 | 10:59am CEST



Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them



14.06.2017 / 10:57

The issuer is solely responsible for the content of this announcement.




1. Details of the person discharging managerial responsibilities / person closely associated



a) Name

Title: Dr.
First name: Helge
Last name(s): Lubenow


2. Reason for the notification



a) Position / status

Position: Member of the administrative or supervisory body


b) Initial notification



3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



a) Name

Epigenomics AG


b) LEI

549300X1C4U862NDLN97 


4. Details of the transaction(s)



a) Description of the financial instrument, type of instrument, identification code

Type: Share
ISIN: DE000A11QW50


b) Nature of the transaction

Share tender for voluntary public takeover offer of Summit Hero Holding GmbH


c) Price(s) and volume(s)

Price(s) Volume(s)
7.52 EUR 45120.00 EUR


d) Aggregated information

Price Aggregated volume
7.52 EUR 45120 EUR


e) Date of the transaction

2017-06-13; UTC+2


f) Place of the transaction

Outside a trading venue





14.06.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Internet: www.epigenomics.com


 
End of News DGAP News Service

35937  14.06.2017 

]]>

© DGAP, source Ad Hoc Disclosures

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EPIGENOMICS AG
06/14 DGAP-DD : Epigenomics AG english
06/14 DGAP-NEWS : Epigenomics AG: Executive Board and Supervisory Board recommend acce..
06/08 DGAP-NEWS : Epigenomics AG: Offer document published for the voluntary public ta..
05/31 31.05.2017 EPIGENOMICS’ ANNUAL : CEO touts takeover offer
05/31 EPIGENOMICS' ANNUAL GENERAL MEETING : CEO touts takeover offer
05/22 DGAP-PVR : Correction of a release from 19.05.2017, 12:58 CET/CEST - Epigenomics..
05/10 EPIGENOMICS : 10.05.2017 Epigenomics AG announces 2017 First Quarter Financial R..
05/10 DGAP-NEWS : Epigenomics AG announces 2017 First Quarter Financial Results
05/08 DGAP-AFR : Epigenomics AG: Preliminary announcement of the publication of quarte..
04/28 EPIGENOMICS : 26.04.2017 Epigenomics AG Reports Results for Financial Year 2016
More news
Sector news : Bio Diagnostics & Testing
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Diagnostics & Testing
News from SeekingAlpha
05/10 Epigenomics reports Q1 results
05/01 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q4 2016 Results - Earnings Call ..
04/27 Epigenomics Goes Private
04/26 Epigenomics reports FY results
02/28 Owlstone Medical Hopes To Breathe Life Into Cancer Diagnosis
Advertisement
Financials (€)
Sales 2017 9,50 M
EBIT 2017 -10,1 M
Net income 2017 -10,1 M
Finance 2017 35,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 145,38
EV / Sales 2017 13,6x
EV / Sales 2018 2,56x
Capitalization 165 M
More Financials
Chart EPIGENOMICS AG
Duration : Period :
Epigenomics AG Technical Analysis Chart | ECX | DE000A11QW50 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 8,66 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gregory K. Hamilton Chief Executive Officer
Heino von Prondzynski Chairman-Supervisory Board
Uwe Staub Chief Operating Officer
Günther Reiter Vice Chairman-Supervisory Board
Ann Clare Kessler Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EPIGENOMICS AG64.31%184
MIRACA HOLDINGS INC.-4.18%2 594
BEIJING STRONG BIOTECH..--.--%1 206
GENSCRIPT BIOTECH CORP11.35%897
SEEGENE INC--.--%861
INNATE PHARMA-14.99%748
More Results